Our work illuminates a new CAMK2D-RNF8-MAD2-mediated mitotic checkpoint regulatory mechanism with relevance to gliomas, and highlights an indirect approach to target this complex therapeutically in GBM. Here, MAD2L1 is linked to glioma.